70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) – Pipeline Review, H2 2016’, provides in depth analysis on 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1)

The report reviews 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

ArQule, Inc.

Astex Pharmaceuticals Inc

Eddingpharm

Merck KGaA

PharmAust Limited

Phoenix Biotechnology, Inc.

Sentinel Oncology Limited

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC

2.7.11.1) Overview 6

Therapeutics Development 7

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC

2.7.11.1) - Products under Development by Stage of Development 7

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC

2.7.11.1) - Products under Development by Therapy Area 8

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC

2.7.11.1) - Products under Development by Indication 9

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC

2.7.11.1) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC

2.7.11.1) - Products under Development by Companies 12

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC

2.7.11.1) - Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 16

Assessment by Molecule Type 17

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC

2.7.11.1) - Companies Involved in Therapeutics Development 18

ArQule, Inc. 18

Astex Pharmaceuticals Inc 19

Eddingpharm 20

Merck KGaA 21

PharmAust Limited 22

Phoenix Biotechnology, Inc. 23

Sentinel Oncology Limited 24

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC

2.7.11.1) - Drug Profiles 25

AT-13148 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

EDP-317 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

M-2698 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

monepantel - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

PBI-05204 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Small Molecule To Inhibit S6K1 For Breast Cancer - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Small Molecules to Inhibit S6K for Oncology - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC

2.7.11.1) - Dormant Projects 34

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC

2.7.11.1) - Discontinued Products 35

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC

2.7.11.1) - Featured News & Press Releases 36

Jul 11, 2016: Juniper Pharma Successfully Completes Manufacture of Reformulated MPL Capsules 36

Jan 29, 2016: PharmAust Limited Announced Quarterly Report & Company Update For the period ended 31 December 2015 36

Nov 26, 2015: PharmAust Appoints GenScript to Complete Further Pre-Clinical Validation for Phase II Trial 37

Jan 17, 2013: Cancer Research UK And Cancer Research Technology Launches Phase I Clinical Trial With AT13148 To Treat Several Cancer Types 38

Jan 16, 2013: Astex Pharma Announces Cancer Research UK And Cancer Research Technology Initiate AT13148 Clinical Trial To Treat Several Cancer Types 39

Jul 10, 2012: Experimental Drug Could Treat Different Cancers, New Research Says 40

Jan 22, 2010: ACT BIOTECH Announces FDA Acceptance Of IND For ACTB1003, A First-in-Class Anti-Cancer Therapeutic 40

Oct 18, 2007: Astex Drug Candidates To Be Featured At The 2007 AACR-NCI-EORTC International Conference 41

Appendix 42

Methodology 42

Coverage 42

Secondary Research 42

Primary Research 42

Expert Panel Validation 42

Contact Us 42

Disclaimer 43

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 15

Number of Products by Stage and Route of Administration, H2 2016 16

Number of Products by Stage and Molecule Type, H2 2016 17

Pipeline by ArQule, Inc., H2 2016 18

Pipeline by Astex Pharmaceuticals Inc, H2 2016 19

Pipeline by Eddingpharm, H2 2016 20

Pipeline by Merck KGaA, H2 2016 21

Pipeline by PharmAust Limited, H2 2016 22

Pipeline by Phoenix Biotechnology, Inc., H2 2016 23

Pipeline by Sentinel Oncology Limited, H2 2016 24

Dormant Projects, H2 2016 34

Discontinued Products, H2 2016 35

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Actions, H2 2016 15

Number of Products by Stage and Routes of Administration, H2 2016 16

Number of Products by Stage and Molecule Type, H2 2016 17

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports